他汀类药物的骨靶向递送:联合用药策略与剂量效应关系

Bone-targeted delivery of statins: combination dosing strategies and dose-effect relationships

传统研究表明,他汀类药物通过影响成骨细胞和破骨细胞的活性对骨代谢产生积极影响。然而,受不良反应和药物疗效的限制,结合纳米技术的骨靶向给药已成为一个新的研究方向。笔者总结了近年来他汀类药物纳米颗粒给药系统的研究情况;纳米技术为未来减少不良反应和提高疗效提供了新的可能性。这些系统利用其精确的药物释放能力有效靶向骨组织,优化疗效并减少全身不良反应。此外,他汀类药物在治疗骨质疏松症时剂量不同的研究也层出不穷。今后,在开发骨靶向给药和纳米技术的组合时,需要考虑他汀类药物的剂量效应关系。总之,他汀类药物在骨质疏松症治疗中的应用是一个多方面的领域,需要综合药物作用机制、剂量效应、纳米技术应用及其临床转化潜力等方面进行深入研究。未来的研究应侧重于探索这些药物的最佳应用,以确保其在调节骨代谢方面的安全性和有效性。

Traditional studies have shown that statins positively affect bone metabolism by affecting the activity of osteoblasts and osteoclasts.However,limited by side effects and drug efficacy,bone-targeted delivery in combination with nanotechnology has become a new research direction.We summarize the research on nanoparticle drug delivery systems in statin delivery in recent years.Nanotechnology offers new possibilities for reducing side effects and improving therapeutic efficacy in the future.These systems use their precise drug-release capabilities to target bone tissue effectively,optimizing therapeutic efficacy and reducing systemic side effects.In addition,there is a proliferation of studies in which statins differ in dose in the treatment of osteoporosis.In the future,we need to consider the dose-effect relationship of statins when developing combinations of bone-targeted drug delivery and nanotechnology.Overall,the use of statins in osteoporosis treatment is a multifaceted field that requires in-depth studies integrating the mechanism of drug action,dose effect,nanotechnology application,and its potential for clinical translation.Future studies should focus on exploring the optimal application of these drugs to ensure their safety and efficacy in regulating bone metabolism.